Summary of product characteristics and Package leaflet
Published:
Changes
Guidance on where to achieve a high quality Norwegian product information. The MAH is responsible for the product information and its quality. The product information includes summary of product characteristics (SmPC), package leaflet (PL) and labelling.
Page contents
High quality Norwegian product information
The product information has to be easy to read and understand for the users. A higher quality of the product information will improve the patient information and contribute to safe use of medicines.
This section will give you some advices on how to create a Norwegian product information of high quality. This includes information about the marketing authorisation holder (MAH) responsibilites, choice of translators, resources, high quality translations of new marketing authorisations (MA) and improving excisting product informations.
Templates, guidelines and other resources on how to write a high quality Norwegian product information can be found under "Resources" further down on the page.
MAH responsibilites
The MAH is responsible for the product information and its quality. The product information includes summary of product characteristics (SmPC), package leaflet (PL) and labelling .
Adequate principles of plain language shall be applied. The MAH is responsible for ensuring that the Norwegian product information is updated in accordance with today's requirements and guidelines before submission.
Summary of product characteristics (SmPC) and Package leaflet (PL)
The product information has to be easy to read and understand for the users. A higher quality of the product information will improve the patient information and contribute to safe use of medicines.
Summary of product characteristics (SmPC)
he target audience for the SmPC are healthcare professionals with medical professional background. The applicant must ensure that the SmPC is of high quality. The concept of plain language should be used.
How to write a good text:
1. Write in Norwegian
It is important that the translated Norwegian text has the same meaning as the English text (faithful translation). There are differences between English and Norwegian grammar. Sentence structure and word order are often different. Direct translation from English to Norwegian can lead to complicated wording and incorrect translation. Split long sentences if possible.
2. Write clearly
Use short sentences and write in an active voice. Avoid using extra nouns. Use verbs instead of nouns where possible. The message should not be disturbed by ambiguous and unclear language.
3. Write to healthcare professionals
Use well-established Norwegian medical terms as much as possible. Some medical terms are identical in English and Norwegian.
4. Standardised translations and abbreviations
The following translations should always be used in the SmPC.
Standardised translations:
active substance – virkestoff
adverse effects/adverse drug reactions – bivirkninger
adverse events – uheldige hendelser
drug/substance – legemiddel
efficacy/effectivity – effekt
herbal medicinal product – plantebasert legemiddel
medicinal product – legemiddel
patient alert card /patient reminder card – pasientkort
Abbreviations:
QD – én gang daglig
BID – to ganger daglig
TID – tre ganger daglig
QID – fire ganger daglig
Package leaflet (PL)
Applicants must ensure that the package leaflet (PIL) always is of high quality. The target audience for the PIL is the patient, therefore the PIL should be easy to read and understand (written in plain language).
How to write a good text:
1. Write in Norwegian
It is important that the translated Norwegian text has the same meaning as the English text (faithful translation). There are differences between Norwegian and English grammar. Sentence structure and word order are often different. Direct translation from English to Norwegian can lead to complicated wording and incorrect translation. Split long sentences if possible.
2. Write clearly
Use short sentences and write in an active voice. Use verbs instead of nouns where possible. The message should not be disturbed by ambiguous and unclear language.
3. Write to the patient
Foreign words are used to a greater extent in the English language, than in Norwegian. Medical terms should always be translated into patient friendly terms and language. The medical term may in some cases be kept in brackets.
Excipients guideline with Norwegian translations
Excipients in medicinal products should be listed qualitatively in the package leaflet. Several of these should be accompanied by information that is of importance to the patient. Such excipients are listed in the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'(External link) (pdf)
New MAs shall comply with this guideline. Existing MAs must update the package leaflet in the next variation concerning the product information or renewal procedure.
Blue box
There is no longer a requirement for Blue box wording in the Norwegian PL's, starting February 12 2020. The MAH's should submit a variation to make sure that the text in the PL is adapted to their product.
The change in Blue box standard wording shall be submitted as a type IB C.I.z or a type II variation that affects the product information. Type IA or a 61(3) notification are not applicable for this matter.
MRP/DCP
For MRP/DCP the Norwegian PL should be a faithful translation of the common text approved in the procedure, i.e. the purely national Blue box wording must be removed from the PL.
National procedure
Blue box wording under section 1 in the PL shall be removed.
In cases where there is aneed to retain important content from the Blue box standard wording, the sentences should be reformulated with adjusted text in accordance withsection 4.7 and 4.9 in the SmPC, respectively:
Information under "Kjøring og bruk av maskiner"
- Shall be adapted to each individual medicinal product
Information under "Dersom du tar for mye av X"
- Shall be adapted to each individual medicinal product
- It is possible to refer to the NorwegianPoison InformationCentrewhen relevant to the medicinal product. If so, the existing Blue box wording can be kept.
For nationally authorised products the proposed wording will be assessed by NoMA.
The Blue box standard wording which was applicable until February 2020:
- Legal status Under punkt 1: Hvis preparatet er unntatt fra reseptplikt må det fremgå av pakningsvedlegget. Tilhørende indikasjonsområde og dosering inkluderes.
- Under punkt 1: "Vær oppmerksom på at legen kan ha foreskrevet legemiddelet til en annen bruk og/eller med en annen dosering enn angitt i pakningsvedlegget. Følg alltid legens forskrivning som er angitt på apoteketiketten."
- Under overskriften: Kjøring og bruk av maskiner: "Du må bare kjøre bil eller utføre risikofylt arbeid når det er trygt for deg. Legemidler kan påvirke din evne til å kjøre bil eller utføre risikofylt arbeid. Les informasjonen i pakningsvedlegget nøye. Er du i tvil må du snakke med lege eller apotek. "
- Under overskriften: Dersom du tar for mye av X: "Kontakt lege, sykehus eller Giftinformasjonen (tlf. 22 59 13 00) hvis du har fått i deg for mye legemiddel eller hvis barn har fått i seg legemiddel ved et uhell. For andre spørsmål om legemiddelet, kontakt lege eller apotek."
Resources
The MAH should focus on readability, harmonised and consistent language when translating to Norwegian. Templates, reference and guidance documents that are instrumental for the preparation of a high quality product information are listed below (not exhaustive):
- Best practice guide on the submission of high quality national translations (CMDh)
- Best practice guide for the submission of high quality national translations for veterinary medicines (CMDv)
- Excipients guideline, Norwegian version(for human medicinal products)
- Appendix II MedDRA terminology to be used in Section 4.8 “Undesirable effects” of SmPC , Norwegian version(for human medicinal products)
- Appendix III Quality review of documents, Norwegian version(for human medicinal products)
For general reference guidelines on how to create a product information
Terms that are approved/preferred for use
- Compilation of QRD decisions on stylistic matters in product information
- Compilation of QRD decisions on use of terms
Recommendations on updating the product information